Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Clostridium Infections

• Treatment of CDI and Recurrence With Fecal Microbiota Transplant Using Promicrobioma
• Xylitol Use for Decolonization of C. Difficile in Patients With IBD
• A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
• Lyophilized Fecal Microbiome Transfer Versus Vancomycin Monotherapy for Primary Clostridioides Difficile Infection in Adults (DONATE)
• Clostridioides Difficile Colonisation
• LMN-201 for Prevention of C. Difficile Infection Recurrence
• Oral Vancomycin vs Placebo in the Prevention of Recurrence of Clostridioides Difficile's Infection
• Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection
• Fecal Microbiota Transplantation Versus Vancomycin or Fidaxomicin in Clostridioides Difficile Infection First Recurrence
• Prevention of C.Difficile Infections With Oral Vancomycine in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
• Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin
• Bezlotoxumab Versus FMT for Multiple Recurrent CDI
• A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)
• Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
• Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection
• Randomized Clinical Trial of Standard FMT Treatments
• Bezlotoxumab Efficacy and Tolerability in Cancer Patient
• Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
• ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection
• Oral Vancomycin Versus Probiotics Versus Placebo for Prevention of Clostridium Difficile Infection in Colonized Patients
• First-in-human Study of VE303 in Healthy Adult Volunteers
• Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection
• Treatment of Mild-moderate Clostridium Difficile Infection (CDI)
• Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years
• Efficacy and Safety of Teicoplanin in CDAD
• Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)
• An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection
• Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection
• PMT for Severe-CDI
• Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.
• Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)
• Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection
• Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection
• ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI
• Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile
• Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD
• Fecal Transplantation for Primary Clostridium Difficile Infection
• Phase 2 Study of VE303 for Prevention of Recurrent Clostridium Difficile Infection
• Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection
• Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients
• The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation
• Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients
• PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol
• To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
• Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
• Use of Bismuth Subsalicylate in Clostridium Difficile Colitis
• Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD)
• Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics
• Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection
• Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection
• TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment
• Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)
• Oral Vancomycin for Preventing Clostridium Difficile Recurrence
• ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
• Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)
• Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
• The ICON Study: Outcomes After FMT for Patients With IBD and CDI
• Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)
• Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
• Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)
• Screening to Prophylax Against Clostridium Difficile Infection -
• Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics
• MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)
• Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile
• SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
• Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea
• A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
• Rectal Bacteriotherapy, Fecal Microbiota Transplantation or Oral Vancomycin Treatment of Recurrent Clostridium Difficile Infections
• Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection
• Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir
• A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
• Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection
• Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
• FMT for Moderate to Severe CDI: A Randomised Study With Concurrent Stool Microbiota Assessment
• A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
• Chlorhexidine Bathing Effect on Clostridium Difficile Rates
• Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection
• Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)
• Expanded Access and Open Label Extension Study of SER-109 to Prevent Recurrent Clostridium Difficile Infection
• SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
• Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection
• Freeze-dried, Capsulized FMT for RCDI
• Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection
• Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury
• IMT for Primary Clostridium Difficile Infection
• FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI
• A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population
• Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection
• A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
• Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients
• Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients
• A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
• Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.
• A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
• Efficacy Study of Alanyl-glutamine Supplementation for the Treatment of C. Difficile Infection
• Study to Investigate the Pharmacokinetics and Safety of Cadazolid in Patients With Clostridium Difficile Infection
• Effect of Acid Suppression Medication on Pediatric Microbiome
• Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea
• Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea
• Efficacy and Safety of Fecal Microbiota Transplantation for Severe Clostridium Difficile Associated Colitis
• Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis
• Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum
• Effects of Gastric Acid on Colonic Microbiome
• The Impact of Proton Pump Inhibitors on the Fecal Microbiome
• Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin
• A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System
• Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum
• Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)
• Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea
• Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe
• A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)
• Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)
• Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
• Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile Infection
• Fidaxomicin to Prevent Clostridium Difficile Colonization
• A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
• Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)
• A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
• Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
• Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin
• Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)
• Study of CB-183,315 in Participants With Clostridium Difficile Infection
• Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections
• Extended Treatment With Vancomycin for Clostridium Difficile Colitis
• Safety and Validation of Efficacy of Oral Administration of the Food Additive Colostrum Derived Anti Clostridium Difficile Antibodies
• Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy
• PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
• A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea
• Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis
• Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease
• A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea
• Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.
• Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)
• Response of Clostridium Difficile Infection to Metronidazole Therapy
• A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
• Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections
• A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea